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Objective: Methods to improve informed consent efﬁciency and effectiveness are needed for pragmatic
clinical trials. We compared informed consent using a tablet computer to a paper approach to assess
comprehension and satisfaction of patients and clinic staff for a future osteoporosis clinical trial.
Methods: Nine community-based practices identiﬁed and recruited patients to compare the informed
consent processes (tablet vs. paper) in a mock osteoporosis clinical trial. The tablet informed consent
included an animation summarizing the trial, complete informed consent document, and questions to
assess and reinforce comprehension of the study. Participants were women age 55 years with 1 year
of alendronate use. We surveyed participants to assess comprehension and satisfaction and ofﬁce staff
for satisfaction and perceived time demands.
Results: The nine practices enrolled 33 participants. There was not a signiﬁcant difference in compre-
hension between the tablet vs. paper informed consent [mean (SD) tablet: 12.2 (1.0) vs. paper: 11.4 (1.7)].
Ofﬁce staff preferred the tablet to the paper informed consent for identifying potential study participants
(two-sided t-test p ¼ 0.02) despite an increased perceived time spent to complete the tablet process
[tablet: 28.3 min (SD 16.3) vs. paper: 19.0 min (SD 6.9); p ¼ 0.08].
Conclusions: Although, there were no signiﬁcant differences in participant satisfaction and compre-
hension with the tablet informed consent compared to a paper informed consent, patients and ofﬁce
staff trended towards greater satisfaction with the tablet informed consent. Larger studies are needed to
further evaluate the utility of electronic informed consent in pragmatic clinical trials.
© 2016 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Pragmatic clinical trials (PCTs) evaluate the real world effec-
tiveness of interventions in the general population rather than the
more homogenous populations used in traditional randomized
controlled trials [1,2]. Including participants from diverse com-
munity settings is needed to maximize the generalizabilitya at Birmingham, Division of
Ofﬁce Tower, 510 20th Street
iner).
n open access article under the CCtypically required of PCTs. However, ensuring efﬁcient and effective
participant informed consent represents a challenging component
of PCTs in settings where the conduct of research is not a primary
function [3e6].
Due to time and resource requirements, the informed consent
process is a barrier to performing PCTs in many practice settings
[7,8]. This is particularly true for many community practices;
especially among practices not well-versed in research procedures
or without dedicated research staff. The traditional informed con-
sent process using a paper form requires dedicated personnel to
explain the study, clarify details, answer questions, and guide pa-
tients through the informed consent process. This requires timeBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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practice setting focused on high throughput clinical care.
As recognized by the Ofﬁce of Human Research Protections,
there are also concerns about whether the current informed con-
sent process leads to fully informed study participants [9]. Thus,
there is a need to improve the efﬁciency of the informed consent
process and improve patient comprehension of clinical research
beneﬁts and risks [10,11]. Electronic tools that provide audiovisual
enhancements to improve patient comprehension can potentially
reduce time demands of busy ofﬁce staff, might alleviate some of
the informed consent barriers, and could improve comprehension,
but they have not been shown to have clear beneﬁt in all studies
[11e16].
To address these evidence gaps in the informed consent process,
we developed a patient self-administered tablet informed consent
tool and conducted a mock study of a future osteoporosis PCT of
bisphosphonate discontinuation versus continuation. We
compared patient comprehension and satisfaction and provider
satisfaction with the electronic informed consent process




We identiﬁed nine community-based practices and asked them
to enroll three participants per informed consent process type
(tablet informed consent process versus traditional paper informed
consent process). In collaboration with a software developer
experienced in direct-to-patient studies (Mytrus, Inc, San Fran-
cisco), we developed an interactive tablet informed consent tool
that included an animated audiovisual summary of a future PCT, the
complete informed consent document, and comprehensive multi-
ple choice questions with feedback to assess and reinforce the key
study consent elements. We surveyed participants' comprehension
and satisfaction immediately following both informed consent
processes. We also surveyed practice staff to assess satisfaction and
perceived time demands following each type of informed consent
process and again at the end of the study to compare the two
processes. All study procedures were approved by the University of
Alabama at Birmingham Institutional Review Board.
Themock study used for this evaluation of the informed consent
processes was a future osteoporosis PCT. The future study does not
include the use of any new treatments or interventions and,
consistent with PCT methodology, the inclusion criteria are mini-
mal. Women enrolling in the mock study were required to provide
social security numbers, which would be used to link to the par-
ticipants' administrative claims data in the future PCT.
2.2. Site recruitment and selection strategy
We identiﬁed community-based practice sites (n ¼ 9: n ¼ 7
“solo”, n ¼ 2 “group”) from the American Academy of Family Phy-
sicians National Research Network (AAFP NRN), the Alabama
Practice Based Research Network (APBRN), and the South Texas
Ambulatory Research Network (STARNet). We selected a conve-
nience sample of eligible sites based on their desire to participate,
their perceived ability to recruit a sufﬁcient number of eligible
participants, and resources available. While the AAFP NRN, APBRN,
and STARNet membership differed slightly in their demographic
characteristics, members of practice based research networks
(PBRNs) have been shown to be representative of community
practices at large [17]. Practices were randomized to start with
either the tablet informed consent process or the paper informedconsent process and then were switched to the alternate informed
consent process after completing 3 participant enrollments, for a
total of 6 participants per practice in order to best assess each
clinic's satisfaction with the both methods.
2.3. Patient recruitment and informed consent process
Practice sites initially identiﬁed eligible participants from their
speciﬁc practice based on the inclusion criteria of the future oste-
oporosis study, i.e. 55 years old and 1 year alendronate use.
When women presented to the clinic, if they were willing to
consider participation, they were ﬁrst provided a paper screening
form, which included 3 questions: (1) Are you currently taking
Alendronate (Fosamax® or Binosto™)?, (2) If yes, have you been
taking Alendronate (Fosamax® or Binosto™) for 1 or more years?,
and, (3) Are youwilling to use a tablet computer to give and receive
medical information? If the women answered “yes” to all three
questions, the clinic staff would then provide them with either the
tablet or paper informed consent. We included the requirement of
willingness to use a tablet computer in the screening questionnaire
in an effort to include women with similar comfort levels with
technology in the two informed consent study groups.
2.4. Electronic informed consent process
The tablet informed consent tool initially presented screening
questions for participants to complete, ﬁrst re-verifying the basic
inclusion criteria, including the participant's age and use of
alendronate for at least 1 year. If the inclusion criteria were
conﬁrmed, the tool then presented an audiovisual description of
the research study using an animated videowith avatars describing
the important details of the study, including the randomization
process and the potential risks and beneﬁts associated with each
arm of the osteoporosis PCT. Participants were provided with ear-
buds to assure only they could hear the audio and a stylus to help
navigate the tablet touchscreen. After the animated video, a com-
plete IRB-approved informed consent document was presented on
the tool. The informed consent also contained seven comprehen-
sion multiple choice questions. The questions focused on the key
components of informed consent: study purpose, randomization,
medication risks, medication beneﬁts, withdrawal from the study,
patient compensation, and conﬁdentiality. If the participant did not
answer a question correctly, she was provided a pertinent “Hint”.
The participant was also offered the option to return to the
informed consent document to review the related information in
greater detail prior to having the question re-asked. There was no
limit to the number of attempts a participant had to answer a
question correctly but questions must be answered correctly before
the participant could continue in the informed consent document.
After completely reviewing the informed consent document and
answering the questions correctly, the participant was asked to
provide her social security number and date of birth and was then
prompted to sign the informed consent document using the touch
screen (with the provided stylus or her ﬁnger). After completion of
the participant component, the staff then veriﬁed all inclusion/
exclusion criteria and co-signed the informed consent document.
Participants were then asked to complete the brief comprehension
and satisfaction assessment (see below).
The number of questions, their content, and how many tries
participants were given to answer questions correctly within the
tablet tool was under the investigators' control. A summary report
from the tablet tool, which included any questions which were
answered wrong, was provided in real time for review by the
enrolling practice staff before co-signing the informed consent.
After the clinic staff signed off on the informed consent, dynamic
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made aware of the study group to which the participant was ran-
domized. The total amount of time spent on the tablet informed
consent process was collected electronically. The tool was devel-
oped in full compliancewith the HIPAA, FDA: Part 11 Compliance 21
CFR 11 (1997), which imposes certain requirements on an entity
when it chooses to maintain FDA-required records and signatures
in electronic form, and uses 256-bit data encryption.2.5. Paper informed consent process
During the paper informed consent process, clinic staff met one-
on-onewith womenwho qualiﬁed for the study based on the initial
screening criteria and the screening form completed upon the
participant's presentation in clinic. After discussing the study with
a clinic staff member, women were provided additional time to
review the informed consent document and ask questions
regarding the study. After review, women agreeing to participate in
the study signed the consent and provided their social security
number and date of birth. As in the tablet consent process, the staff
veriﬁed all inclusion/exclusion criteria and then co-signed the
informed consent document. Participants then also completed the
brief comprehension and satisfaction assessment as the tablet
participants did after completing the entire informed consent
process (see below).2.6. Survey assessment of patient comprehension and satisfaction
We assessed all participants upon completion of assigned
informed consent process for comprehension of the informed
consent elements/study aims, satisfaction with the mode of
informed consent, perceived time requirement for completion of
the informed consent, ease of completion, and importance of the
informed consent in determining a willingness to participate in a
future research study through surveys. The survey comprehension
questions were multiple choice and were based on the validated
Health-Information Technology Usability Evaluation Scale (Health-
ITUES) [18,19] and Quality of Informed Consent (QuIC) [20] surveys.
Seven of the 38 survey questions in the brief survey administered at
the conclusion of the consent process were the same questions
included in the tablet informed consent tool. Additional survey
questions measured each of the basic components of informed
consent: who to contact with questions/problems regarding the
study, coverage of potential study-related injuries, and procedures
speciﬁc to the study. We also assessed basic knowledge/experience
with electronic tools through questions regarding use and posses-
sion of smart phones and home computers. All questions other than
the ﬁrst 13multiple choice and true/false comprehension questions
were administered using a 7-point Likert response set. Participants
in each process were also asked to provide their perceived time to
complete the informed consent process in minutes.
In both informed consent processes, participants were recruited
and presented the informed consent as if they were enrolling in the
future osteoporosis clinical trial. They were initially “blind” to the
actual purpose of this pilot study, namely to compare informed
consent methodologies. Following completion of the informed
consent process for this mock study, all participants were debriefed
to the true nature of the experiment by practice staff and the par-
ticipants were offered re-consent to complete the informed con-
sent comprehension and satisfaction surveys. None of the
participants had access to the Informed Consent document at the
time of completion of these surveys.2.7. Survey assessment of physician and practice staff satisfaction
Practice sites were surveyed by phone three times during the
study: after enrolling 3 participants using the paper process, after
enrolling 3 participants using the tablet process, and after
completing both processes/end of the study. The practice site sur-
veys included 10 questions using a 7-point Likert response set and
covered site satisfaction, perceived time requirements for the
informed consent process, conﬁdence in administering the
informed consent, clinic disruption, ease of the informed consent
process for the clinic staff and participants, and the willingness to
use a similar informed consent process for future clinical research.
An additional question was also included regarding the perceived
amount of time required for participants to complete the informed
consent process.
The end of study survey was administered immediately after
completion of the second informed consent process and the
applicable process survey. The end of study survey consisted of ﬁve
questions directly comparing the tablet informed consent process
to the traditional paper informed consent process. The questions
included ease of the informed consent process, efﬁciency of each
process, helpfulness of each process, time required to complete
each process, and the appeal of each process to participants, using a
7-point Likert response set.
Given the limited participant enrollment period of this pilot, not
all sites completed recruitment using both informed consent
methods, and thus did not complete both sets of surveys. Only staff
that participated in both phases of this pilot were administered all
surveys.
2.8. Data analysis
We used descriptive statistics to summarize the characteristics
of participants and practices at baseline. Participant characteristics
were compared between those who completed the tablet informed
consent process to those who completed the paper informed con-
sent process. An overall summary score for actual patient
comprehension was calculated from the cumulative number of
correct responses on the ﬁrst 10 survey questions and mean scores
were compared by group. Likert-scale responses on participant and
practice surveys were treated as interval-level data and mean re-
sponses to the seven-point questions were compared. We deter-
mined statistical signiﬁcance using two sided t-test (unless
otherwise stated), or primarily Fisher's exact test due to small cell
sizes. All analyses were conducted in SAS v.9.3 (Carey, NC).
3. Results
Nine practices participated, with clinical sites located in three
states (Alabama, Colorado and Texas). The majority (78%) of sites
were solo practices (Table 1). All practices were recruited from
practice based research networks and the primary specialty of the
recruitment sites was Family Practice, except for one Gynecology
practice site. All sites had been involved in some form of clinical
research in the past.
The sites enrolled 33 women (n ¼ 15 tablet informed consent;
n¼ 18 paper informed consent) (Table 1). There were an additional
10 women who completed the initial screening questionnaire
based on age/medication use eligibility but who were ineligible for
the mock study based on an unwillingness to use a tablet for
informed consent (n ¼ 7), or an unwillingness to provide social
security number (n ¼ 3) (Fig. 1). Mean (SD) age of the women
enrolled was 69.1 (SD 7.1) years in the tablet group and 71.4 (SD 8.8)
years in the paper group and 68.7 (SD 7.7) years in the 10 women
who were ineligible based on additional screening. Approximately
Table 1
Participant and practice characteristics by method of informed consent
administration.
Tablet (n ¼ 15) Paper (n ¼ 18)
Participant characteristics
Age, Mean (SD) 69.1 (7.1) 71.4 (8.8)
Race/ethnicity, n (%)
Black 2 (13.3) 2 (11.1)
White 13 (86.7) 16 (88.9)
Employment, n (%)
Full-time 4 (26.7) 4 (22.2)
Not employed 10 (66.7) 13 (72.2)
Part time 1 (6.7) 1 (5.6)
Education, n (%)
Less than high school 1 (6.7) 1 (5.6)
High school or GED 4 (26.7) 5 (27.8)
Some college 7 (46.7) 5 (27.8)
4 year college or higher 3 (20.0) 7 (38.9)
Marital status
Single or widowed 3 (20.0) 4 (22.2)
Separated 0 (0.0) 1 (5.6)
Married or cohabitating 6 (40.0) 9 (50.0)
Divorced 5 (33.3) 4 (22.2)
Missing 1 (6.7) 0 (0.0)
Use a personal computer, *n (%) 12 (80.0) 8 (44.4)
Use a smartphone, n (%) 9 (60.0) 6 (33.3)
Practice characteristics (n ¼ 9) n (%)
Clinic size
Group practice 3 (33.3)
Solo practice 6 (66.7)
Practice type
Family practice 8 (88.9)
Gynecology/Obstetrics 1 (11.1)
*Non-signiﬁcant trends (p-value ¼ 0.07; using Fisher's exact test) in the proportion
of women with experience with a home computer between those randomized to
tablet consent versus those assigned to paper consent.
Fig. 1. Consort diagram showing the number of patients recruited into the study and reasons for dropout.
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similar among both groups. There was a trend, but not a signiﬁcant
difference, in the proportion of women with experience with a
home computer between those randomized to tablet consent
versus those assigned to paper consent (80% vs. 44%; p ¼ 0.07)
(Table 1). There was a non-signiﬁcant difference in smartphone
users among the same group (60% vs. 33%, respectively, p ¼ 0.17).
We found no signiﬁcant differences in overall demographiccharacteristics (shown in Table 1) between the 10 women who
began the process but were not enrolled and the women who
completed the full informed consent process (data not shown).
Overall, participant comprehension and satisfaction with both
informed consent processes was high. Based on the results from the
13 comprehension questions, therewas a non-signiﬁcant difference
in comprehension between the two groups. The tablet informed
consent group had a mean of 12.2 (SD 1.0) correct answers
compared to the paper informed consent group mean of 11.4 (SD
1.6) correct answers out of 13 possible. Participants using the tablet
trended toward higher mean perceived comprehension in all cat-
egories (Fig. 2A: comprehension). Although not statistically sig-
niﬁcant, mean satisfaction in all categories was slightly greater
among participants using the tablet consent process (Fig. 2B:
satisfaction). Among the participants, the mean perceived time to
complete the informed consent process (to the point of randomi-
zation) for the mock study using both methods was nearly iden-
tical: 22.9 min (SD 9.4) for the tablet group and 23.1 min (SD 14.6)
for the paper group, (two-sided t-test p ¼ 0.97). The actual time for
completion was not available for the paper informed consent pro-
cess; on average, women interacted with the tablet for 13 min and
7 s (SD 8.8).
Provider and staff satisfaction was measured in the six practices
(n¼ 5 “solo” practices and n¼ 1 “group” practice) that were able to
enroll participants using both of the informed consent processes
and completed the ﬁnal surveys. Similar trends in greater satis-
faction with the tablet informed consent process that were seen in
patient participants were seen from practice site staff. For physician
and practice staff, the mean perceived time for patients to complete
the informed consent process was 28.3 min (SD 16.3) for the tablet
group and 19.0 min (SD 6.9) for the paper group (two-sided t-testp ¼ 0.08). Physician and staff reported the tablet tool was more
beneﬁcial in helping to recruit and enroll appropriate study par-
ticipants (Fig. 3). Speciﬁcally, providers and clinic staff signiﬁcantly
preferred the tablet (mean 6.6, SD 0.5) to the paper informed
consent (mean 6.0, SD 0.8) (two-sided t-test p ¼ 0.02) for identi-
fying potential study participants, based on responses to a 7-point
Likert scale, with 7 being “Extremely Satisﬁed” and 1 being “Not
Satisﬁed”. Other questions of satisfaction including the integration
Fig. 2. A. Perceived Participant Comprehension (n ¼ 33). Differences detected were not signiﬁcant. PHI, Protected Health Information. B. Participant Reported Satisfaction by Mode
of Informed Consent.
Fig. 3. Provider Overall Preference for Informed Consent Completion in Tablet vs. Traditional Paper Consent (n ¼ 12). Favors tablet ¼ 7, Favors Paper ¼ 1, Neutral ¼ 4, Mean (SD).
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understanding patients had; the time required for patients to
complete the informed consent process for the osteoporosis
research study; and, their satisfaction with the informed consent
process trended towards favoring the tablet process but results
were not signiﬁcant (Fig. 3).
4. Discussion
We conducted a pragmatic randomized study of a tablet
informed consent process versus traditional paper informedconsent to determine overall efﬁciency of the two approaches and
to determine if participant comprehension and participant and
practice site satisfaction were similar or different using a mock
future osteoporosis PCT. Despite similar or greater perceived time
spent completing the tablet informed consent process, we found a
non-signiﬁcant trend towards participant satisfaction and provider
and clinic staff satisfaction with the tablet informed consent pro-
cess compared to the paper informed consent. Physicians and clinic
staff noted signiﬁcantly greater satisfaction in identifying potential
study participants with the tablet informed consent process.
Most studies of multimedia informed consent processes were
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single uncontrolled medical intervention rather than a clinical trial
[21,22]. A systematic review of 12 trials using multimedia informed
consent reported that signiﬁcant improvements in study compre-
hension were not seen immediately after completion of the
informed consent process [9]. The addition of a video to the paper
informed consent in two of four studies showed that sustained
comprehensionwas improved when participants were re-surveyed
a week following the informed consent completion [9]. With the
use of tablet technology, participants have the ability to not only
read the consent but see and hear about study details using the
animated narrative of study procedures.
Recently, a study on the use of a tablet informed consent tool,
similar to the one we developed for our study, showed signiﬁcantly
improved comprehension of study procedures and risks for a
clinical trial of cancer chemotherapy when compared to a paper
consent in a randomized study involving 55 patients [14]. In that
study, participants were clinical research personnel and other
volunteers from a single institution; all were aware that they were
not being recruited for an actual study but were reviewing mate-
rials to assess their comprehension and recall of the informed
consent details after use of a new tool [14]. Moreover, the partici-
pants were excluded if they had the disease of interest for the study.
In this cancer treatment study, the addition of audiovisual aids led
to improved participant comprehension and satisfaction when
compared to a paper informed consent despite increased time to
complete the informed consent process with the tablet [14]. This
study differed from our study in which we speciﬁcally recruited
participants who were eligible and interested in enrolling in the
trial. Notwithstanding, the improved comprehension seen in this
study that also used tablet technology supports ﬁndings from our
more generalizable study, in which we observed mainly non-
signiﬁcant trends between the two informed consent groups but
we were limited by a smaller sample size.
Use of an electronic or tablet-based informed consent has
several potential advantages with regard to standardizing informed
consent administration and conduct in multi-site trials in addition
to participant-related beneﬁts. With the use of tablet technology,
participant knowledge can be assessed in real time to determine
whether informed consent materials are understood through
comprehension questions, as we did in our study. If a lapse in un-
derstanding is noted, reinforcement of speciﬁc details can occur in
real-time. Electronic informed consent also allows for real-time
monitoring of participant recruitment with immediate recording
of site/participant interactions; enables more efﬁcient initial
screening; all collected information obtained has an electronic time
and date stamp; and, the process can be managed from any loca-
tion. There is also the opportunity to have access to the informed
consent in multiple languages within a single device.
Our study has several limitations. This was a mock trial to
determine the best mode of informed consent to use in a future
osteoporosis clinical trial. Therefore, during the participant
recruitment process, participants were recruited and presented
the informed consent as if they were enrolling for the future
osteoporosis clinical trial, keeping them “blind” to the true nature
of the experiment. This was done to test and obtain the least
contrived participant input during an informed consent process.
Although such an approach should improve generalizability, it is
possible that the mock nature of our study could have become
contaminated, if patients became unblinded to our true study
hypothesis on consent methodology through discussions with
clinic staff or otherwise. We did not directly assess anxiety to our
methods of informed consent, but it is an important component
that possibly contributed, in either direction, to overall satisfac-
tion with our tool compared to the traditional approach toobtaining informed consent. Although there were non-signiﬁcant
differences between informed consent groups with regard to
prior home computer use, there was a trend and proportionately
more women had home computers in the tablet informed consent
group than the paper informed consent group (80% vs. 44.4%). It is
unclear the degree to which this potential imbalance in computer
experience may have impacted participants' preferences for the
tablet informed consent.
The number of patient participants was limited to include only
those who would agree to use a tablet (an inclusion criteria for all
study participants, with 16% (n ¼ 7) refusing). As with home
computer exposure, this potentially limits generalizability to a
younger or more afﬂuent patient population who may be more
comfortable with newer technologies. However, our data do not
support this concern since the mean ages in both groups ranged
from 69 to 71, which was similar in range to those who did not
participate in the study due to an unwillingness to use a tablet for
consent. Although not a limitation of our speciﬁc study, a tablet-
based informed consent, in general, has the potential limitation of
the expense of developing the initial infrastructure and technol-
ogy to manage and validate online documents. Additionally, there
may be challenges regarding the need for a stable secure Wi-Fi
network or cellular data coverage to allow for data delivery and
updates to electronic consents. However, there is growing use of
electronic technology in most clinical practices and a general
movement toward the use electronic informed consent, as
demonstrated by the FDA report guiding the use of e-consent
[23].
An additional limitation is the method used for site selection
and recruitment. Convenience sampling may have limited the
generalizability (and inﬂuenced the external validity) of the study.
Although our study was conducted among community practices
well distributed among rural, urban, and suburban locations and
across several U.S. regions, the number of “solo” practices may have
impacted the ability to meet recruitment goals, and the number of
“group” practices was relatively small and therefore may not be
generalizable to all practice sites. Additionally, each “solo” practice
was different in clinic size and operation, whichmay have impacted
timely recruitment of participants as all practices were given the
freedom to operationalize the trial to best ﬁt their clinic workﬂow.
While the variability between these methods and how they were
implemented may have impacted recruitment in this pilot study,
allowing busy clinical practices to have the freedom to conduct
clinical trials as they see ﬁt minimized disruption to patient care
and created a more pragmatic design. While future study designs
could incorporatemore rigid recruitment and operational methods,
further research into the workﬂow/operations of successful com-
munity based practices is needed to better understand how to best
implement recruitment for pragmatic clinical trials into every day
practice. Future studies with larger sample sizes will be needed to
further evaluate electronic informed consent for PCTs.
In summary, we found good feasibility and satisfaction of using
electronic technology aiming towards more efﬁcient PCT patient
recruitment and randomization and more efﬁcient and effective
informed consent processes. Despite the clinic staffs having a
longer perceived time requirement for participants to complete the
informed consent process with a tablet computer, there was
signiﬁcantly greater satisfaction by practices for identifying po-
tential study participants with the tablet computer; and while not
signiﬁcant, participant mean satisfaction in all categories was
slightly greater among participants using the tablet consent pro-
cess. Use of electronic informed consent may not be beneﬁcial for
all clinical studies; but in certain settings, electronic informed
consent has the potential to improve participant comprehension
and research site satisfaction.
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